Ticker

Redmile Group increased its Nurix Therapeutics holding by 4,415,514 shares; the estimated trade value was $63.43 million based on quarterly average pricing. Meanwhile, the quarter-end position value rose by $119.55 million, reflecting the combined impact of share purchases and Nurix Therapeutics' price movement.

Executives from Nurix Therapeutics (NASDAQ: NRIX) used a recent discussion on the company's immunology and inflammation (I&I) efforts to outline why the firm believes targeted protein degradation could offer advantages over conventional small-molecule inhibition in inflammatory diseases. While Nurix is often associated with its oncology programs, company leadership argued its I&I pipeline-centered on BTK, IRAK4, and

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) CFO Houte Hans Van sold 3,661 shares of the stock in a transaction on Friday, January 30th. The shares were sold at an average price of $16.60, for a total value of $60,772.60. Following the completion of the transaction, the chief financial officer owned 45,427 shares of

Nurix Therapeutics, Inc. (NASDAQ: NRIX - Get Free Report) insider Gwenn Hansen sold 4,895 shares of the stock in a transaction that occurred on Friday, January 30th. The shares were sold at an average price of $16.60, for a total transaction of $81,257.00. Following the completion of the transaction, the insider owned 83,672 shares of the

Nurix Therapeutics (NASDAQ: NRIX - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings. Analyst Ratings This is a summary of recent